Last Updated August 2022
This document is intended as an educational reference for Advanced Practice Providers (APPs) and is not meant to guide individual practice or supersede the decisions of individual practitioners.
The use of neurostimulation devices has become commonplace in Epilepsy Centers. APPs are frequently involved in the clinical management of the three currently FDA-approved devices for epilepsy, which include Vagus Nerve Stimulation (VNS), Responsive Neurostimulation (RNS), and Deep Brain Stimulation (DBS).
Each device is considered an adjunctive therapy for medically refractory focal epilepsy when surgical resection or ablation of the seizure focus is not feasible. The goal of therapy is to reduce the frequency and severity of disabling seizures.